Studies of nosocomial outbreaks of hepatitis B in nursing homes in Germany suggest a major role of hepatitis B e antigen expression in disease severity and progression.

[1]  G. Leroux-Roels.  Old and new adjuvants for hepatitis B vaccines , 2015, Medical Microbiology and Immunology.

[2]  F. Heinemann,et al.  Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. , 2014, Vaccine.

[3]  P. Karayiannis,et al.  HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. , 2014, World journal of gastroenterology.

[4]  P. Patel,et al.  Hepatitis B outbreak associated with a home health care agency serving multiple assisted living facilities in Texas, 2008-2010. , 2014, American journal of infection control.

[5]  R. Janssen,et al.  Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. , 2013, Vaccine.

[6]  H. Ullum,et al.  Infectivity of blood products from donors with occult hepatitis B virus infection , 2013, Transfusion.

[7]  Yonghui Zhang,et al.  Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule , 2012, Human vaccines & immunotherapeutics.

[8]  A. Moorman,et al.  Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak. , 2012, Vaccine.

[9]  Q. Ma,et al.  Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen , 2012, Journal of medical virology.

[10]  T. Jovanović,et al.  COMPLETE GENOME SEQUENCES AND PHYLOGENETIC ANALYSIS OF HEPATITIS B VIRUS ISOLATES FROM SERBIA , 2012 .

[11]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[12]  W. Gerlich,et al.  Simple confirmatory assay for anti-HBc reactivity. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  D. Nebáznivá,et al.  Vaccination of patients with diabetes mellitus--a retrospective study. , 2011, Central European journal of public health.

[14]  K. Lole,et al.  An outbreak of hepatitis B with high mortality in India: association with precore, basal core promoter mutants and improperly sterilized syringes , 2011, Journal of viral hepatitis.

[15]  M. Ramsay,et al.  Five hepatitis B outbreaks in care homes in the UK associated with deficiencies in infection control practice in blood glucose monitoring , 2010, Epidemiology and Infection.

[16]  G. Xia,et al.  Acute Hepatitis B Outbreaks Related to Fingerstick Blood Glucose Monitoring in Two Assisted Living Facilities , 2010, Journal of the American Geriatrics Society.

[17]  A. Moorman,et al.  Nonhospital Health CareAssociated Hepatitis B and C Virus Transmission: United States, 19982008 , 2009, Annals of Internal Medicine.

[18]  R. Malekzadeh,et al.  Clinical significance of precore and core promoter mutations in genotype D hepatitis B‐related chronic liver disease , 2008, Journal of viral hepatitis.

[19]  H. Norder,et al.  D2: major subgenotype of hepatitis B virus in Russia and the Baltic region. , 2008, The Journal of general virology.

[20]  A. Heath,et al.  An international collaborative study to establish the 2nd World Health Organization International Standard for hepatitis B virus DNA nucleic acid amplification technology‐based assays , 2008, Vox sanguinis.

[21]  J. Bayas,et al.  A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. , 2008, Kidney international.

[22]  Wen-Hsiung Li,et al.  The nonsynonymous/synonymous substitution rate ratio versus the radical/conservative replacement rate ratio in the evolution of mammalian genes. , 2007, Molecular biology and evolution.

[23]  C. Galli,et al.  Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[24]  B. Song,et al.  Sequential Accumulation of the Basal Core Promoter and the Precore Mutations in the Progression of Hepatitis B Virus-Related Chronic Liver Disease , 2006, Intervirology.

[25]  R. Ueda,et al.  Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection , 2006, Hepatology.

[26]  B. Genton,et al.  Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. , 2006, Vaccine.

[27]  W. Gerlich,et al.  Outbreak of hepatitis B in a nursing home associated with capillary blood sampling , 2006, Epidemiology and Infection.

[28]  P. Coursaget,et al.  Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes , 2004, Intervirology.

[29]  F. Chisari,et al.  A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Gerlich,et al.  Transmission of Hepatitis B Virus 2 Months Prior to Hepatitis Surface Antigen Positivity of Donor Blood , 2003, Transfusion Medicine and Hemotherapy.

[31]  P. Wingfield,et al.  Diversity of core antigen epitopes of hepatitis B virus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  F. Zoulim,et al.  Genome Replication, Virion Secretion, and e Antigen Expression of Naturally Occurring Hepatitis B Virus Core Promoter Mutants , 2003, Journal of Virology.

[33]  A. Heath,et al.  An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques , 2001, Vox sanguinis.

[34]  P. Pumpens,et al.  Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. , 2000, The Journal of general virology.

[35]  D. Blondin,et al.  Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B , 2000, Hepatology.

[36]  G. Leandro,et al.  Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B , 1999, Journal of viral hepatitis.

[37]  M. Chen,et al.  Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication , 1996, Journal of virology.

[38]  S. Günther,et al.  A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients , 1995, Journal of virology.

[39]  U. Akarca,et al.  Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Purcell,et al.  The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. , 1993, Virology.

[41]  C. Galli,et al.  Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. , 1993, Journal of hepatology.

[42]  C. Trépo,et al.  Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal. , 1992, Virology.

[43]  G. Wunderlich,et al.  Genomic variability in the preS1 region and determination of routes of transmission of hepatitis B virus. , 1992, The Journal of general virology.

[44]  M. Nassal.  The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly , 1992, Journal of virology.

[45]  J. Wands,et al.  A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. , 1991, The New England journal of medicine.

[46]  H. Schaller,et al.  Translational inactivation of RNA function: Discrimination against a subset of genomic transcripts during HBV nucleocapsid assembly , 1990, Cell.

[47]  R. Bartenschlager,et al.  A short cis‐acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. , 1990, The EMBO journal.

[48]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[49]  W. Gerlich,et al.  Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections , 1986, Journal of clinical microbiology.

[50]  M. Favero,et al.  SURVIVAL OF HEPATITIS B VIRUS AFTER DRYING AND STORAGE FOR ONE WEEK , 1981, The Lancet.

[51]  B. Schwartz.  Letter: Ondine's curse. , 1976, Lancet.